Aquestive Therapeutics adds Rich Daly to board of directors

Aquestive Therapeutics, Inc. (NASDAQ: AQST) said on September 29, 2026 that its board elected Richard J. Daly as a director, effective October 14, 2026. The Board of Directors elected Richard J. Daly as a director effective October 14, 2026, and he will serve as a Class I director with a term expiring at the Company's 2028 Annual Meeting of Stockholders.¹

With the addition, the Board approved an increase in the number of directorships from seven to eight effective October 14, 2026, after which the Board will consist of eight directors, seven of whom are independent directors.¹ The board separately concluded that Daly has no material relationship with the company affecting his independence, so he qualifies as an independent director under Nasdaq's listing rules.¹

Daly currently holds the title of President of Global Rare Disease at Angelini Pharma S.p.A., a role he took on after Angelini acquired Catalyst Pharmaceuticals, Inc., where he had served as President and Chief Executive Officer.¹ At Catalyst, he oversaw commercial and business-development activities, including the U.S. launch of Agamree®.¹ Earlier in his career, Daly held senior roles at Takeda Pharmaceutical Company Limited, including Executive Vice President, Americas, where he directed the integration of TAP Pharmaceuticals into Takeda, and at AstraZeneca, where as President of the U.S. Diabetes business he oversaw the launches of Farxiga® and Myalept®.¹

Aquestive CEO Daniel Barber said Daly's commercial and operating perspective will be valuable as the company continues preparations for the potential launch of Anaphylm, if approved by the FDA.¹ Under the company's director compensation program, Daly will receive an initial grant of 57,000 stock options under the 2018 Equity Incentive Plan, as amended.¹